Aamir Mahmood
President & CEO
Good morning, and welcome to the Q2 2026 Acarix Earnings Call. I appreciate everybody joining. For our new investors and for those who have been with us a while, I always like to start out with a little bit of an assessment as to who we are and what we do. The CADScor System produced by Acarix is a highly high-fidelity acoustic device that has the ability to listen into the coronary arteries of the patient’s heart at point of care. And what we’re able to derive from our negative predictive value of 96.2% is very high productivity in regards to being able to rule out coronary artery disease at point of care just in a few minutes, 4 to 6 minutes on average. We have over 15 years of R&D, over 45 patents and well over 60,000 assessments worldwide, along with 6,000 patients in clinical trials continually building our robust outcomes.
From a regulatory standpoint, we are FDA approved as well as CE marked, and we actually just announced a couple of additional ones we’ll talk about in the future. We’re a Class II medical device, and we have a CPT code in the United States for reimbursement. We are headquartered in Sweden. We have our R&D manufacturing in Denmark, and we continually focus on deploying global sales.
Really exciting news that just came out Monday, a couple of days ago that we have received regulatory approval in the United Arab Emirates or the UAE. This is our first entry into the Gulf region, which is an extraordinary region that has a very significant focus in regard to health care and providing health care
